Preview Newsletter
Xarelto Media Scan 8-7-15
-
Xarelto Side Effects Lawsuit: Study Suggests Drug Could Be Linked To Eye Bleeding
Aug 1, 2015 | Digital Journal
By Marc Goldich
A new study published in the June edition of JAMA Ophthalmology suggests that Xarelto could lead to internal bleeding of the eye, according to BloodThinnerHelp.com. The study was conducted by Dr. Judy H. Jun and Dr. John C. Hwang who noticed that several of their patients had suffered a form of internal bleeding called a vitreous hemorrhage while switching from warfarin to rivaroxaban. -
Xarelto Side Effects: Lawsuit Claims Drug Caused Injury From Internal Bleed
Aug 3, 2015 | KYTX-TV
By Marc Goldich
BloodThinnerHelp.com reports on a lawsuit which has been filed in federal court against the manufacturers of Xarelto, a popular blood thinner drug sold in the US. A Texas woman filed the complaint in federal court for the Eastern District of New York under docket number 1:14-CV-04525, alleging that Xarelto led her to suffer internal bleeding which subsequently caused injuries. -
Xarelto Side Effects: Two New Studies Link Blood Thinner To Stomach And Eye Bleeding
Aug 5, 2015 | The Legal Herald
By Marc Goldich
As thousands of Xarelto lawsuits are filed in the federal MDL and state court mass tort programs around the country, two new studies have been released linking Xarelto to two additional side effects. Specifically, one study concluded that Xarelto (Rivaroxaban) increases the risk of an eye bleed in elderly people, and another study concluded that patients who took Xarelto may have a doubling of the risk of a stomach bleed as compared to those taking the anti coagulant Warfarin. -
Baron & Budd Investigating Potential Xarelto Lawsuits
Aug 6, 2015 | StreetInsider.com
By Devin Downey
The blood-thinning medication Xarelto, distributed in the U.S. by Janssen Pharmaceuticals, has allegedly been linked to several severe complications, including hemorrhagic strokes, excessive internal bleeding and death. The national law firm of Baron & Budd is investigating potential lawsuits on behalf of patients who have suffered adverse reactions to the drug. -
A New Study Raises Concerns About Xarelto Side Effects In Pregnant Women
Aug 6, 2015 | Digital Journal
By Marc Goldich
BloodThinnerHelp.com reports that a new study has been released raising concerns that the active drug Xarelto (Rivaroxaban) crosses the placental barrier to the fetus in pregnant women who take the blood thinner. "While the study did not look at the dangers of Xarelto permeating the placental barrier, it did call for such a study to be carried out given the statistically significant findings that the drug in fact does enter the fetus," commented Marc Goldich from BloodThinnerHelp.com. -
Xarelto Side Effects: 350 Lawsuits Filed In Philadelphia Mass Tort
Aug 7, 2015 | The Legal Herald
By Marc Goldich
The number of lawsuits filed in the Philadelphia mass tort litigation regarding Xarelto side effects has grown to nearly 350 individual cases, according to data from the Philadelphia Court of Common Pleas. -
New Evident Shows that Xarelto Can Be Passed Down From Mother to Fetus
Jul 31, 2015 | Texas Injury Law Blog
By Majed Nachawati
A recent study has revealed that mothers who take Xarelto can pass down the drug to their unborn child. When ingested during pregnancy, the anticoagulant transfers back and forth across the placenta between a mother and her fetus. The study was done by a research team at The Motherisk Program at the Hospital for Sick Children in Toronto and published most recently in the American Journal of Obstetrics & Gynecology. They initially began the study in order to discover the degree of transfer of the drug and what potential side effects would occur. -
Miss. Widow Sues Pharma Giants for Husband’s Xarelto Death
Jul 31, 2015 | Top Class Actions
By Amanda Antell
Missouri widow Dixie S. is suing Bayer Pharmaceuticals and Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals, alleging that the defendants’ product caused the death of her husband. Dixie claims that as a direct result of using Xarelto, her husband developed, and later died from, internal bleeding injuries. Dixie’s husband, Jay S., was prescribed Xarelto in December 2012 to treat his atrial fibrillation and to ultimately prevent stroke. Initially, Jay responded well to the Xarelto treatment. He followed the advice of his physician and all prescription instructions; unfortunately, not long after he started the blood-thinner, Jay started experiencing complications. -
Xarelto Bleeding Lawsuits Grow, Along With Sales
Aug 3, 2015 | Bernstein Liebhard LLP
At least 1,200 U.S. plaintiffs have filed Xarelto lawsuits after allegedly suffering serious complications due to its use. Yet the burgeoning litigation shows no signs of slowing the drug’s sales, which were up more than 43% during the second quarter of this year. According to an investor report issued by Bayer last week, all of the pending Xarelto cases seek compensatory and punitive damages for personal injuries allegedly related to the use of the medication, including cerebral, gastrointestinal or other bleeding and death. The company expects that more cases will eventually be filed. At lease six Xarelto class actions that put forth similar allegations are also pending in Canadian courts. -
Xarelto Lawsuit Information | Xarelto FAQ
Aug 4, 2015 | YouTube
By TorHoerman Law
Lawyers in the xarelto lawsuit answer client's FAQ regarding the xarelto litigation. TorHoerman Law -
Xarelto Side Effects Lawsuit Filed For Wrongful Death
Aug 4, 2015 | The Legal Herald
By Marc Goldich
A lawsuit has been filed in the Xarelto Multidistrict Litigation (MDL No. 2592) by a man who alleges that Xarelto caused the wrongful death of his father. The plaintiff in this particular case (2:15-cv-00886) seeks to recover monetary, compensatory and punitive damages incurred from injuries suffered as a result of Xarelto. -
Xarelto Bellwether Trial Dates Have Been Set; The First Is Scheduled For August 2016
Aug 4, 2015 | The Levensten Law Firm
By Scott Levensten
In December 2014 the U.S. Judicial Panel on Multidistrict Litigation began consolidating the Xarelto lawsuits. The lawsuits were consolidated into the Eastern District of Louisiana. Since December, any complaint that has been filed about Xarelto have been sent to Louisiana for the proceedings. Since all of these cases will be in one court, the proceedings will be more efficient because there will be less conflicts and errors. -
Xarelto Lawyer
Aug 5, 2015 | Tate Law Group
Pharmaceutical companies have a responsibility to develop prescription drugs that are safe for consumers. The makers of Xarelto, Bayer and Janssen Pharmaceuticals, are defendants in several Xarelto lawsuits because of the alleged deffective and dangerous nature of the drug. If you or a loved one has experienced a severe bleeding occurrence after taking Xarelto, you may be entitled to take legal action with a Xarelto lawyer. -
Three Plaintiffs File Joint Xarelto Bleeding Lawsuit
Aug 6, 2015 | Top Class Actions
By Ashley Vanover
A Xarelto bleeding lawsuit was filed jointly by three plaintiffs who allege Bayer Healthcare and Janssen Pharmaceuticals failed to provide adequate warnings about the safety risks associated with the use of the popular blood thinner. Plaintiffs Evelyn F. of Georgia, Henrietta F. de Louisiana, and Tommy O. of Texas, all allege the companies failed to warn patients and provide information to physicians related to the increased risks of internal Xarelto bleeding events associated with taking the anticoagulant medication. -
Nearly 1,500 People Have Joined Xarelto Litigation
Aug 6, 2015 | The Clark Firm
In a regulatory filing issued in July, Bayer HealthCare said about 1,200 people who used Xarelto have filed lawsuits. Another 200 people joined the litigation earlier this week. Lawsuits involve serious side effects of Xarelto, including bleeding in the brain, intestines, and uncontrollable bleeding resulting in death. As of July 17, six lawsuits seeking class action status were also filed in Canada. -
Xarelto, Pradaxa Bleeding Risks The Same As Warfarin: Study
Aug 7, 2015 | AboutLawsuits.com
By Irvin Jackson
New research suggests that the blood thinners Xarelto and Pradaxa are no safer than warfarin when it comes to bleeding and arterial thromboembolic events like heart attacks and strokes. The findings raise further concerns about the new-generation anticoagulants, as they lack an approved reversal agent, which makes it harder for doctors to stop bleeding events that do occur. In a study published in the American Heart Association’s medical journal Circulation on July 21, researchers from the France’s National Health Insurance Strategy and Research Department report that they found no significant difference in the rate of bleeding events, strokes or heart attacks among patients using either Xarelto, Pradaxa or some form of vitamin K agonist (VKA), which is an older class of blood thinners that includes Coumadin (warfarin).
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
-
Xarelto Side Effects Lawsuit: Study Suggests Drug Could Be Linked To Eye Bleeding
Aug 1, 2015 | Digital Journal
By Marc Goldich
A new study published in the June edition of JAMA Ophthalmology suggests that Xarelto could lead to internal bleeding of the eye, according to BloodThinnerHelp.com.
The study was conducted by Dr. Judy H. Jun and Dr. John C. Hwang who noticed that several of their patients had suffered a form of internal bleeding called a vitreous hemorrhage while switching from warfarin to rivaroxaban.
The study notes that the risk of vitreous hemorrhage may be heightened during a period when a patient is transitioning from the use of warfarin to rivaroxaban.
This is one of several recent publications which have suggested a link between the use of Xarelto and dangerous internal bleeding side effects.
To read the abstract of the study click here.
Xarelto: A New Type of Blood Thinner
Xarelto (rivaroxaban) is a new type of prescription blood thinner known as a Novel Oral Anticoagulant (NOAC) and is commonly prescribed to patients for the prevention of blood clots and treatment of other related medical conditions.
While Xarelto has had major success since its debut in the US market, several recently published studies have linked the drug to dangerous side effects including internal bleeding.
Legal Action Taken Against Drug Manufacturers
As a result of the revealing studies, many people across the country who may have been harmed by Xarelto have filed lawsuits against the companies responsible for manufacturing and distributing the drug in the US.
Stephen A. Sheller, Esq. commented, “The total number of lawsuits filed in relation to Xarelo side effects has grown exponentially over the last few months which is in part due to studies like the one performed by Dr. Jun and Dr. Hwang.”
Sheller is a sponsor of BloodThinnerHelp.com and represents both those who wish to file a Xarelto side effects lawsuit.
For more information about current Xarelto litigation visit BloodThinnerHelp.com or contact Marc Goldich, Esq. at (866) 425-8902.
http://www.digitaljournal.com/pr/2631013
-
Xarelto Side Effects: Lawsuit Claims Drug Caused Injury From Internal Bleed
Aug 3, 2015 | KYTX-TV
By Marc Goldich
August 03, 2015 – /PressAdvantage/ – BloodThinnerHelp.com reports on a lawsuit which has been filed in federal court against the manufacturers of Xarelto, a popular blood thinner drug sold in the US.
A Texas woman filed the complaint in federal court for the Eastern District of New York under docket number 1:14-CV-04525, alleging that Xarelto led her to suffer internal bleeding which subsequently caused injuries.
This lawsuit, like many others filed in relation to Xarelto, claims that drug companies Janssen Pharmaceuticals and Bayer AG (co-manufacturers of Xarelto) were negligent in failing to perform sufficient safety testing on the drug.
Additionally, the lawsuit alleges that these companies acted negligently by failing to warn the public of dangerous side effects associated with their drug.
In this particular case, a woman from Texas (the plaintiff) was prescribed Xarelto by her doctor for the prevention of blood clots. After taking the drug for five months the plaintiff suffered an internal bleed which resulted in serious injury.
Xarelto Side Effects: A Growing Concern
Xarelto has been prescribed more than 11,000,000 times in America since its initial FDA approval just four years ago.
However, Xarelto’s commercial success in the US market has come under question after recently published studies linked the drug to serious side effects.
Uncontrollable internal bleeding is among the most serious side effect associated with Xarelto and has been reported by many patients prescribed to the drug.
Dangerous Drug Litigation
The revealing studies linking Xarelto to dangerous side effects has led many to take legal action against the drug companies responsible for manufacturing and distributing Xarelto.
“Complaints relating to Xarelto’s side effects continue to be filed in federal courts throughout America,” said Marc Goldich, Esq.
“We are currently assisting as many people as possible who have been harmed by Xarelto’s side effects by helping them to pursue justice,” he concluded.
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.cbs19.tv/story/29695254/xarelto-side-effects-lawsuit-claims-drug-caused-injury-from-internal-bleed
-
Xarelto Side Effects: Two New Studies Link Blood Thinner To Stomach And Eye Bleeding
Aug 5, 2015 | The Legal Herald
By Marc Goldich
As thousands of Xarelto lawsuits are filed in the federal MDL and state court mass tort programs around the country, two new studies have been released linking Xarelto to two additional side effects. Specifically, one study concluded that Xarelto (Rivaroxaban) increases the risk of an eye bleed in elderly people, and another study concluded that patients who took Xarelto may have a doubling of the risk of a stomach bleed as compared to those taking the anti coagulant Warfarin.
The Hun and Hwang Study: Eye Bleeds – A New Xarelto Side Effect
In June 2015, the results of a study conducted by two doctors, Dr. Judy Hun and Dr. John Hwang, were published in JAMA Opthalmology. The study was performed on elderly patients between the ages of seventy and eighty who switched their blood thinner from Warfarin to Xarelto. The doctors reported that many of the patients began suffering bleeds while they were being weaned off Warfarin.
The specific bleed occurred in the eye and is known as a vitreous hemorrhage. The doctors stated that it occurred in their patients as soon as they began taking Xarelto. This eye bleed happens between the retina of the eye and the eye lens.
To read more about the study click here.The BMJ Study: Stomach Bleeds
Prior to the release of the Hun and Hwang study, another study was released in April 2015. This study was reported in the BMJ where 46,000 people were assessed. This study concluded that the results could not rule out a more than doubling of the risk of a stomach bleed with Xarelto as compared to Warfarin.
What Are The Other Xarelto Side Effects?
As detailed in another article on The Legal Herald: “What Are The Side Effects Referenced In Xarelto Lawsuits“, the lawsuits filed to date all show common fact patterns with respect to the injuries and side effects suffered by those who took the blood thinner. One of the more common side effects is abdominal bleeding or a gastrointestinal bleed. This type of bleeding can be very dangerous, as it is difficult to diagnose early. Often, the patient is elderly and will exhibit weakness and symptoms of anemia given the blood loss.
One of the main issues with Xarelto is that the bleeding is uncontrollable. The lawsuits all claim that the manufacturers J&J and Bayer AG did not provide the medical community with a means of reversing the anti-coagulation effect of the drug. This often results in extreme life saving measures having to be taken by medical staff to treat a patient suffering from an internal bleed if they have Xarelto in their blood stream.
Other serious side effects that are common are:
Pulmonary embolism
Stroke
Brain bleed or subdural hematoma – this often results in serious pressure on the brain requiring a craniotomy and many transfusions
Spinal or epidural hematoma – we have seen many cases of paralysis from pooling of blood on the spinal chord.
rectal, vaginal or colon bleeds – many women have presented with such bleeds
liver dysfunction
For a detailed analysis of each condition, you can visit BloodThinnerHelp.com.
As always we will keep you updated with breaking news in the Xarelto litigation.
http://legalherald.com/xarelto-side-effects-two-new-studies-link-blood-thinner-to-stomach-and-eye-bleeding/
-
Baron & Budd Investigating Potential Xarelto Lawsuits
Aug 6, 2015 | StreetInsider.com
By Devin Downey
The blood-thinning medication Xarelto, distributed in the U.S. by Janssen Pharmaceuticals, has allegedly been linked to several severe complications, including hemorrhagic strokes, excessive internal bleeding and death. The national law firm of Baron & Budd is investigating potential lawsuits on behalf of patients who have suffered adverse reactions to the drug.
The U.S. Food and Drug Administration approved Xarelto for use in 2011 to prevent blood clots from developing and to treat existing blood clots in patients. However, the drug has allegedly been associated with several complications, including bleeding in the brain and stomach as well as other cases of uncontrolled internal bleeding. In an article that appeared in the June 15 issue of JAMA Ophthalmology, doctors reported several elderly patients suffered bleeding between the retina and lens of the eye after moving to Xarelto from another blood-thinning medication, warfarin.
Xarelto has been marketed by Janssen (a subsidiary of Johnson & Johnson) as a superior anti-coagulant to warfarin, which is marketed under the brand name of Coumadin. warfarin has been prescribed since the 1950s, but users of the medication need to be regularly monitored by a physician. Xarelto is marketed as more convenient than warfarin because patients purportedly do not need to be monitored nearly as often. While warfarin can cause similar bleeding events, those complications can typically be reversed through the immediate administration of high doses of Vitamin K or frozen plasma. Those options are not effective in treating bleeding events associated with Xarelto, and there is no other known antidote.
“There have been far too many instances of patients taking this drug and suffering devastating side effects,” said Russell Budd, president and managing shareholder of the national law firm of Baron & Budd. “Pharmaceutical companies owe it to patients to introduce the safest possible products to the marketplace, and must be held accountable when they are found to be negligent in this obligation.”
Call the national law firm of Baron & Budd at 1.866.700.8994 if you or a loved one has suffered adverse effects from taking Xarelto, or send an email to info@baronbudd.com. One of our attorneys will let you know if you qualify to file a lawsuit against the manufacturer.
ABOUT BARON & BUDD, P.C.
The law firm of Baron & Budd, P.C., with offices in Dallas, Baton Rouge, Austin and Los Angeles, is a nationally recognized law firm with a nearly 40-year history of "Protecting What's Right" for people, communities and businesses harmed by negligence. Baron & Budd's size and resources enable the firm to take on large and complex cases. The firm represents individuals and government and business entities in areas as diverse as dangerous pharmaceuticals and medical devices, environmental contamination, the Gulf oil spill, financial fraud, overtime violations, deceptive advertising, automotive defects, trucking accidents, nursing home abuse, and asbestos-related illnesses such as mesothelioma.
http://www.streetinsider.com/Press+Releases/Baron+%26amp%3B+Budd+Investigating+Potential+Xarelto+Lawsuits/10790086.html
-
A New Study Raises Concerns About Xarelto Side Effects In Pregnant Women
Aug 6, 2015 | Digital Journal
By Marc Goldich
BloodThinnerHelp.com reports that a new study has been released raising concerns that the active drug Xarelto (Rivaroxaban) crosses the placental barrier to the fetus in pregnant women who take the blood thinner.
"While the study did not look at the dangers of Xarelto permeating the placental barrier, it did call for such a study to be carried out given the statistically significant findings that the drug in fact does enter the fetus," commented Marc Goldich from BloodThinnerHelp.com.
This study was presented at the annual scientific meeting of the Canadian Society of Pharmacology and Therapeutics in Winnipeg, MB, Canada in June 2014. To read the study, click here.
Xarelto: Side Effects & Concerns About The Blood Thinner
Xarelto is a new blood thinner that is marketed as a one pill a day solution without frequent blood monitoring or major dietary changes. As a result, this drug has been extremely popular because of its convenience. However, as we have seen with a flurry of reported adverse events, and filed lawsuits, the drug's convenience may come at a cost.
The drug has been in the spotlight because of the side effects which allegedly cause hospitalization, serious injury, and even death. Over 500 lawsuits have been filed around the U.S. alleging that Xarelto caused uncontrollable bleeding which could have been avoided had the manufacturers adequately warned about the risks of taking the drug.
Xarelto’s warning label contains a note stating that patients who are pregnant should use the blood thinner with caution because of the potential of a hemorrhage or delivery with an anticoagulant that is not reversible. In addition, the Food & Drug Administration has classified Xarelto as a category C drug. This means that animal studies have evidenced adverse effects on the fetus. While there have been no human studies performed as to the safety of Xarelto and how it affects the fetus, this latest study gives rise to great concern given we now know that the drug readily passes into the fetus and back to the mother.
Common Side Effects Identified In Xarelto Lawsuits
BloodThinnerHelp.com has analyzed many fact patterns of its clients and complaints filed in federal and state court around the country. The following are the most common side effects reported:
Abdominal bleeding
Gastrointestinal bleeding (GI Bleed)
Brain hemorrhage / bleeds / subdural hematoma
Blood Clots
Stroke
Heart Attack
Spinal Bleeds / Epidural Hematoma
Eye / Retina bleeds
Stomach Bleeds
As the litigation continues to progress through the civil court system, it remains to be seen what will happen. Last year, a drug in the same class as Xarelto, Pradaxa, settled similar claims with 4,000 individuals for $650 million.
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.digitaljournal.com/pr/2637766
-
Xarelto Side Effects: 350 Lawsuits Filed In Philadelphia Mass Tort
Aug 7, 2015 | The Legal Herald
By Marc Goldich
The number of lawsuits filed in the Philadelphia mass tort litigation regarding Xarelto side effects has grown to nearly 350 individual cases, according to data from the Philadelphia Court of Common Pleas.
About Xarelto Lawsuits
Xarelto is a prescription anticoagulant (also known as blood thinner) which was approved by the FDA in 2011 and has had commercial success in the US market ever since.
The drug is typically prescribed to prevent certain types of blood clots including deep vein thrombosis and pulmonary embolism. Xarelto is also commonly prescribed to prevent the formation of blood clots in patients that have gone under a knee or hip replacement surgery.
However, as many recent studies have shown, Xarelto may be associated with serious side effects including irreversible internal bleeding. These findings have led many to file lawsuits against the companies responsible for producing and distributing Xarelto in America. In addition to other allegations, these complaints assert that the companies acted negligently by failing to warn about the risks associated with the drug.
On January 22nd, 2015 the Philadelphia Court of Common Pleas consolidated several lawsuits pertaining to the allegedly dangerous side effects associated with Xarelto.
There were initially 75 separate cases consolidated in the mass tort litigation in Philadelphia, however the total number of cases involved has continuously grown since then and now includes almost 350 complaints.
Additionally, more than 400 Xarelto lawsuits have been consolidated in a multidistrict litigation based in the U.S. District Court for the Eastern District of Louisiana.
Representation For Plaintiffs In Xarelto Litigation
“Several new studies have been released within the last few months linking Xarelto to potentially dangerous side effects which could lead to injury or death,” commented Stephen A. Sheller, Esq.
“Our firm is currently helping plaintiffs who wish to file complaints in the Philadelphia Mass Tort Group, as well as those who wish to file a claim in the MDL based in Louisiana.”
Please direct all questions about this article and the Xarelto litigation to Marc Goldich at 866-425-8902.
http://legalherald.com/xarelto-side-effects-350-lawsuits-filed-in-philadelphia-mass-tort/
-
New Evident Shows that Xarelto Can Be Passed Down From Mother to Fetus
Jul 31, 2015 | Texas Injury Law Blog
By Majed Nachawati
A recent study has revealed that mothers who take Xarelto can pass down the drug to their unborn child. When ingested during pregnancy, the anticoagulant transfers back and forth across the placenta between a mother and her fetus. The study was done by a research team at The Motherisk Program at the Hospital for Sick Children in Toronto and published most recently in the American Journal of Obstetrics & Gynecology. They initially began the study in order to discover the degree of transfer of the drug and what potential side effects would occur.
Although they were able to prove that Xarelto did transfer from a mother to her fetus, they will need to conduct additional studies to better understand whether or not it would be safe to administer Xarelto to a pregnant woman. In some high-risk pregnancies, anti-coagulants are a necessary treatment for expecting mothers. Unfortunately, Xarelto does not yet have an antidote and if it is given to pregnant women, it may pose a risk for her fetus. For this reason, researchers have indicated that further studies are needed to better understand this risk.
Legal Commentary
Xarelto attorneys within our firm are studying, examining and investigating current Xarelto claims on behalf of people and their families who may have been injured by the drug. Some of the side effects include hemorrhaging, internal bleeding, stroke and or death. If you or a loved one has experienced any side effects while taking Xarelto, contact our Xarelto lawyers to discuss the facts of your potential case. We are available by phone for a free consultation at1.866.705.7584 or by email at mn@fnlawfirm.com.http://www.txinjuryblog.com/2015/07/articles/dangerous-drugs/new-evident-shows-that-xarelto-can-be-passed-down-from-mother-to-fetus/
-
Miss. Widow Sues Pharma Giants for Husband’s Xarelto Death
Jul 31, 2015 | Top Class Actions
By Amanda Antell
Missouri widow Dixie S. is suing Bayer Pharmaceuticals and Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals, alleging that the defendants’ product caused the death of her husband. Dixie claims that as a direct result of using Xarelto, her husband developed, and later died from, internal bleeding injuries.
Dixie’s husband, Jay S., was prescribed Xarelto in December 2012 to treat his atrial fibrillation and to ultimately prevent stroke. Initially, Jay responded well to the Xarelto treatment. He followed the advice of his physician and all prescription instructions; unfortunately, not long after he started the blood-thinner, Jay started experiencing complications.
In early May 2013, Jay went to the hospital with bleeding concerns. He was put in the intensive care unit, where he was diagnosed with intracerebral hemorrhage. He was immediately taken off Xarelto. Despite hospital treatment, Jay died in late May from his bleeding injuries allegedly caused by Xarelto.
Dixie is now suing the drug’s manufacturers for the wrongful death of her husband, as well as for causing her personal mental anguish, pain, and suffering connected to her husband’s injuries and subsequent death. In the Xarelto lawsuit, Dixie claims that the anticoagulant caused her husband to suffer a fatal attack; furthermore, she alleges her husband had no prior awareness of the drug’s potential side effects. Dixie insists that her husband never would have taken Xarelto if he had known the risks, and that the drug’s manufacturers failed to provide warnings or relevant drug saefty studies.
Overview of Xarelto Bleeding Complications
Xarelto was approved by the FDA in 2011 as a direct competitor to America’s original anticoagulant, Warfarin, and the first new-generation anticoagulant, Pradaxa. Pradaxa was released a year earlier by German pharmaceutical giant Boehringer Ingelheim, which opened the way for several major American pharmaceutical companies to develop their own new-generation anticoagulants.
These newer anticoagulants touted speed and convenience, but some consumers and physicians now claim that those benefits came with a steep price. In contrast to Warfarin, new-generation anticoagulants do not have an approved stopping agent. A case of uncontrollable internal bleeding could lead to potential fatalities, such as Jay’s. Additionally, Warfarin patients were often required to see their physicians regularly for dose adjustments; experts believe that if Xarelto and other new-generation anticoagulants had these same requirements, there would significantly less incidents of internal bleeding.
For being allegedly responsible for her husband’s death, and for manufacturing an unreasonably dangerous product, Dixie is suing Bayer and Janssen Pharmaceuticals. The charges include negligence, wrongful death, false advertising, concealing information, and misrepresenting a product.
This Xarelto Lawsuit is Case No. 2:15-cv-01734-EEF-MBN, in the U.S. District Court for the Eastern District of Louisiana.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/81915-miss-widow-sues-pharma-giants-for-husbands-xarelto-death/
-
Xarelto Bleeding Lawsuits Grow, Along With Sales
Aug 3, 2015 | Bernstein Liebhard LLP
At least 1,200 U.S. plaintiffs have filed Xarelto lawsuits after allegedly suffering serious complications due to its use. Yet the burgeoning litigation shows no signs of slowing the drug’s sales, which were up more than 43% during the second quarter of this year.
According to an investor report issued by Bayer last week, all of the pending Xarelto cases seek compensatory and punitive damages for personal injuries allegedly related to the use of the medication, including cerebral, gastrointestinal or other bleeding and death. The company expects that more cases will eventually be filed. At lease six Xarelto class actions that put forth similar allegations are also pending in Canadian courts.
If these lawsuits are impacting sales at all, the effect is negligible. In the second quarter of 2015, the drug generated $600 million in Revenue for Bayer.
“We are marketing Xarelto in 60-70 countries at the moment so the introduction has been very successful,” Bayer’s CEO told CNBC late last month. “In the United States at the moment, Xarelto has more market share than all of the other oral anti-coagulants combined of our competitors,”
Xarelto Bleeding Allegations
Xarelto is a new generation blood thinner that has been available in the U.S. since 2011. Like any anticoagulant, some patients treated with Xarelto may experience serious internal hemorrhaging. However, no reversal agent has yet been approved for Xarelto bleeding. By contrast, hemorrhaging caused by a much older blood-thinning medication called warfarin can be stopped by the administration of vitamin K.
Plaintiffs have accused Bayer of wrongly marketing Xarelto as a superior alternative to warfarin, despite the absence of an antidote for its potentially life-threatening bleeding side effects. Plaintiffs also take issue with marketing claims that characterized the medication as easier to use than warfarin because it does not require regular blood monitoring to ensure patients are receiving the appropriate dose. Xarelto lawsuits charge that a regular testing protocol would actually benefit patients using the drug.
On the federal level, more than 500 Xarelto injury claims have been filed in a multidistrict litigation now underway in the U.S. District Court, Eastern District of Louisiana, where trials could begin next August. Additional cases are pending in various state courts, including more than 200 that have been filed in mass tort litigation underway in the Philadelphia Court of Common Pleas.
Learn How to Join the Xarelto Litigation
Bernstein Liebhard LLP is representing alleged victims of Xarelto bleeding, and our attorneys continue to offer free legal reviews to alleged victims of this medication. To learn if you qualify to file a Xarelto lawsuit, please give our office a call at (888) 881-3077.
http://www.thexareltolawsuit.com/xarelto-bleeding-lawsuits-grow-along-with-sales/
-
Xarelto Lawsuit Information | Xarelto FAQ
Aug 4, 2015 | YouTube
By TorHoerman Law
Attorney Steven Davis from the firm TorHoerman Law answers questions about the Xarelto lawsuits and provides opportunities for viewers to undergo a case evaluation.
https://www.youtube.com/watch?v=qKN3fZRbEbE
-
Xarelto Side Effects Lawsuit Filed For Wrongful Death
Aug 4, 2015 | The Legal Herald
By Marc Goldich
A lawsuit has been filed in the Xarelto Multidistrict Litigation (MDL No. 2592) by a man who alleges that Xarelto caused the wrongful death of his father.
The plaintiff in this particular case (2:15-cv-00886) seeks to recover monetary, compensatory and punitive damages incurred from injuries suffered as a result of Xarelto.
The plaintiff’s father, who was prescribed Xarelto by his healthcare provider for the treatment of atrial fibrillation, died in March of 2013 due to a major internal bleed.
Like several other Xarelto complaints filed thus far, this case alleges that defendants Bayer AG and Janssen Pharmaceuticals failed to perform sufficient safety testing on their prescription drug.
Furthermore, the lawsuit claims that these drug companies acted negligently by putting forth misleading advertisements about Xarelto and by failing to warn consumers about significant dangers associated with the drug which they had known about.
The plaintiff asserts that his father would not have taken Xarelto had he been made aware of the significant risks associated with the drug.
Xarelto: Is It A Dangerous Drug?
Xarelto (rivaroxaban) is a blood thinner drug which is often prescribed to reduce the risk of stroke and systemic embolism in patients with atrial fibrillation.
The blood-thinning medication is also commonly prescribed for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Xarelto is part of a new class of blood thinners known as Novel Oral Anticoagulants (NOACs), which have had commercial success in the US market in recent years.
However, revealing studies have linked the blockbuster drug to potentially harmful side effects including irreversible internal bleeding.
A growing number of lawsuits have now been filed in relation to these allegedly dangerous side effects.
In fact, there are now more than 400 complaints which have been consolidated in the Xarelto MDL based in the US District Court for the Eastern District of Louisiana.
“We expect the number of cases involved in the MDL to continue to grow at a rapid pace as more and more people learn about the studies linking Xarelto to dangerous side effects,” commented Stephen A. Sheller, Esq. who represents plaintiffs in Xarelto lawsuits.
For more information about this article or Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://legalherald.com/xarelto-side-effects-lawsuit-filed-for-wrongful-death/
-
Xarelto Bellwether Trial Dates Have Been Set; The First Is Scheduled For August 2016
Aug 4, 2015 | The Levensten Law Firm
By Scott Levensten
In December 2014 the U.S. Judicial Panel on Multidistrict Litigation began consolidating the Xarelto lawsuits. The lawsuits were consolidated into the Eastern District of Louisiana. Since December, any complaint that has been filed about Xarelto have been sent to Louisiana for the proceedings. Since all of these cases will be in one court, the proceedings will be more efficient because there will be less conflicts and errors.
Both sides have been doing their best to continue pushing the litigation in the right direction. There are over 500 Xarelto cases. All the plaintiffs who are part of the lawsuit have claimed that Xarelto is unsafe becuase of the bleeding risks and no antidote being available. Plaintiffs have also claimed that the manufacturers of the anticoagulant did not provide enough warnings about the serious side effects of Xarelto, including internal bleeding, hemorrhages, and blood clots.
The first bellwether trial has been scheduled for August 1, 2016. Whenever pre-trial proceedings are placed into a litigation like Xarelto, the purpose is to have as much valuable resources as possible in order to present everything to the juries. Every side will then make a decision on how the juries will conduct themselves regarding the proofs and evidence.
As it has been noted, Xarelto was approved by the FDA in 2011. It was approved because it was supposed to reduce blood clots in the patients who were having knee surgery or hip surgery. It was then approved to lower the stroke risks in patients with non-valvular AF. However, it has now been linked to hundreds of unfortunate events that have led to hospitalization and deaths.
If you or a loved one suffered from severe bleeding after taking Xarelto, please contact the Levensten Law Firm at 215-545-5600 or on our home page, or at www.xareltoinjurylawyer.com to learn how to file a claim for compensation for your injuries.
http://levenstenlawfirm.com/xarelto-bellwether-trial-dates-have-been-set-the-first-is-scheduled-for-august-2016/
-
Aug 5, 2015 | Tate Law Group
Pharmaceutical companies have a responsibility to develop prescription drugs that are safe for consumers. The makers of Xarelto, Bayer and Janssen Pharmaceuticals, are defendants in several Xarelto lawsuits because of the alleged deffective and dangerous nature of the drug. If you or a loved one has experienced a severe bleeding occurrence after taking Xarelto, you may be entitled to take legal action with a Xarelto lawyer.
Xarelto was introduced in the United States market in July of 2011, and is part of a class of drugs called New Oral Anticoagulants (NOACs). This class of NOACs, which also includes Pradaxa and Eliquis, has been marketed as the next generation of blood-thinning drugs and has been prescribed to prevent pulmonary embolism and deep vein thrombosis, as well as strokes in patients suffering from atrial fibrillation, and for patients who had undergone knee and hip replacement procedures. The manufacturing company, Bayer and Janssen Pharmaceuticals – a division of Johnson & Johnson – reported that approximately 130,000 prescriptions were written for Xarelto in the first three months of 2012 in the U.S. alone.
However, Xarelto carries a significant risk of severe, and sometimes even fatal, internal bleeding – and there is no reversal agent available if serious bleeding occurs with Xarelto use. In 2013, the Institute for Safe Medication Practices (ISMP) announced that the U.S. Food and Drug Administration (FDA) reported receiving 680 serious adverse event reports from individuals who alleged to have suffered adverse events while taking Xarelto. That number quickly rose to more than 1,800 adverse events linked to Xarelto, the most common events were pulmonary embolism, deep vein thrombosis, gastrointestinal hemorrhage, and hemorrhage. Hospitalization was reported in 891 of these events; 183 patients lost their lives.
As a result of many adverse event reports, the FDA required the makers of Xarelto to issue ‘black box’ warnings about the potential hazards of using Xarelto. The ‘black box’ warning is the most urgent type of warning that is issued by the FDA. This warning advised that Xarelto print advertisement was “false or misleading because it minimizes the risks associated with Xarelto and makes a misleading claim” regarding blood monitoring and “no dosage adjustments.” To date, more than 21,000 adverse events have been linked to Xarelto.
Xarelto Side Effects
The reason Xarelto is so much more dangerous than other anticoagulants on the market, is that it causes uncontrollable bleeding that cannot be reversed. Other blood thinners can be controlled with Vitamin K, but Xarelto does not respond to Vitamin K. There is no antidote for excessive bleeding caused by taking Xarelto, leaving patients at a much greater risk of bleeding to death.
Commonly reported side effects of Xarelto include:
Back pain
Bleeding gums
Bloody stools
Prolonged bleeding from cuts
Nose bleeds
Bloody coughs
Xarelto Lawsuit
Several plaintiffs have filed lawsuits against the makers of Xarelto. They allege the drug caused cerebral hemorrhaging, gastrointestinal bleeding and fatalities. Due to the severe blood thinning effects of Xarelto, plaintiffs further claim:
The makers of Xarelto continued to market the drug as being safe after they found out it was not
The makers of Xarelto did not give doctors actions to take to assist patients who experienced excessive bleeding as a result of taking Xarelto
The makers of Xarelto are motivated by profits more than maintaining the safety of Xarelto
Consumers were not warned by the makers of Xarelto about the dangers associated with taking the drug
Pharmaceutical companies must be held accountable for any action that causes harm and loss to consumers. It is the right of any Xarelto user who has been harmed to file a Xarelto lawsuit against the companies Bayer and Janssen Pharmaceuticals. If you or a loved one have suffered as a result of taking Xarelto, you may be eligible to be compensated for pain, suffering, past/future medical bills, and funeral expenses. Filing a Xarelto lawsuit does not take away the pain you have suffered, but it can ease your financial and emotional burdens. If you have been harmed by Xarelto, you may be able to receive compensation. Contact an experienced Xarelto lawyer today.
If you or a loved one suffered serious injury after using Xarelto, please contact the attorneys at the Tate Law Group toll free at (866)610-7101 for your confidential and free consultation.
http://tatelawgroup.com/medical-lawsuits-savannah-ga/xarelto-lawyer/
-
Three Plaintiffs File Joint Xarelto Bleeding Lawsuit
Aug 6, 2015 | Top Class Actions
By Ashley Vanover
A Xarelto bleeding lawsuit was filed jointly by three plaintiffs who allege Bayer Healthcare and Janssen Pharmaceuticals failed to provide adequate warnings about the safety risks associated with the use of the popular blood thinner.
Plaintiffs Evelyn F. of Georgia, Henrietta F. de Louisiana, and Tommy O. of Texas, all allege the companies failed to warn patients and provide information to physicians related to the increased risks of internal Xarelto bleeding events associated with taking the anticoagulant medication.
De acuerdo con la Xarelto sangrado demanda, plaintiff Evelyn F. used Xarelto for almost two weeks in June 2014 and suffered a gross hematuria. Plaintiff Henrietta F. ingested Xarelto for a little over a year and suffered a hemorrhage in her kidney in August 2014 and plaintiff Tommy O. took Xarelto for about nine months before he suffered progressive chronic anemia and a consistent decrease in hemoglobin levels in September 2014.
These three plaintiffs all directly attribute their bleeding events to Xarelto and claim that Bayer and Janssen failed to include a “Boxed Warning” about Xarelto bleeding. The plaintiffs further claim the drug should not be sold and that Bayer and Janssen negligently promoted Xarelto as safe when they allegedly knew the blood thinner could cause life-threatening bleeding events.
Evelyn, Henrietta and Tommy have added their Xarelto bleeding claims to the multidistrict litigation currently pending in the U.S. Tribunal de Distrito para el Distrito Este de Louisiana [In re: Xarelto (Rivaroxaban) Litigios Productos Defectuosos,MDL 2592, En la caja. 14-md-2592].Sangrado Xarelto Eventos
Xarelto (rivaroxaban) was first approved by the FDA in July 2011 como un medicamento recetado con tres usos principales: para reducir el riesgo de coágulos sanguíneos y accidentes cerebrovasculares en pacientes con fibrilación auricular, para el tratamiento de la trombosis venosa profunda y la embolia pulmonar, y para reducir el riesgo de coágulos de sangre en los pacientes sometidos a cirugía de reemplazo de rodilla o cadera.
Xarelto pertenece a una clase de anticoagulantes llamados inhibidores del factor Xa directo. Algunas veces conocido como anticoagulantes, anticoagulantes interfieren con la coagulación normal de la sangre.
La coagulación es esencial si una persona es detener la hemorragia de una herida abierta, pero algunas personas experimentan coagulación cuando no se lesionan. La fibrilación auricular es una enfermedad del corazón que se caracteriza por un ritmo cardíaco irregular que puede causar que la sangre se estanque en el corazón y puede conducir a la formación de coágulos.
Si éstos viajan al cerebro, que pueden causar un accidente cerebrovascular. Los coágulos de sangre que se desarrollan en las piernas (La trombosis venosa profunda) y la embolia pulmonar (coágulos de sangre en los pulmones) puede causar complicaciones graves y / o la muerte si no se trata.
Cuando las personas experimentan efectos secundarios que sospechan que fueron causados por una prescripción o medicamentos de venta libre, ellos o sus médicos pueden reportar los eventos a la FDA. Estos eventos se registran en los acontecimientos adversos Reporting System FDA (AEIR).
De los más de 1,800 eventos adversos ligados a Xarelto, los eventos más frecuentes fueron embolismo pulmonar (386 informes), La trombosis venosa profunda (279 informes), gastrointestinal hemorrhage (107 informes) y hemorragia (107 informes). La hospitalización se informó en 891 de estos eventos, y 183 de los pacientes perdieron la vida.Demandas de sangrado Xarelto
The Xarelto bleeding lawsuit is seeking compensatory, económico, and punitive damages for the drug companies’ allegedly fraudulent and reckless disregard for the safety and welfare of Xarelto users.
La Xarelto Sangrado Demanda es asunto n. 2:15-cv-02975-EEF-MBN in the U.S. District Court for the Eastern Division of Louisian and the Xarelto MDL is Case No. 14-md-2592, In re: Xarelto(Rivaroxaban) Litigios Productos Defectuosos, en la U.S.. Tribunal de Distrito para el Distrito Este de Louisiana.
http://topclassactions.com/es/lawsuit-settlements/lawsuit-news/85305-three-plaintiffs-file-joint-xarelto-bleeding-lawsuit/
-
Nearly 1,500 People Have Joined Xarelto Litigation
Aug 6, 2015 | The Clark Firm
In a regulatory filing issued in July, Bayer HealthCare said about 1,200 people who used Xarelto have filed lawsuits. Another 200 people joined the litigation earlier this week.
Lawsuits involve serious side effects of Xarelto, including bleeding in the brain, intestines, and uncontrollable bleeding resulting in death. As of July 17, six lawsuits seeking class action status were also filed in Canada.
As of July 15, there were over 800 lawsuits pending in a centralized federal Multi-District Litigation (MDL No. 2592) in Louisiana, overseen by Judge Eldon E. Fallon.
However, earlier this week, four separate lawsuits were filed on behalf of another 198 people. Injuries blamed on Xarelto included bleeding complications, including intestinal bleeding, hematuria, subdural hematoma, bleeding in the brain, and death.
The first “bellwether” trial is expected to begin on August 1st, 2016. Another three trials are scheduled to begin between then and October 17th, 2016. The outcomes are not binding on other cases, but they can help lawyers negotiate settlements or other agreements to resolve the litigation without taking every case to trial.
Xarelto has been marketed as superior to warfarin, but there are some major differences. One is thatwarfarin can be reversed with a dose of Vitamin K in an emergency, but Xarelto has no reversal agent. If a patient on Xarelto starts bleeding or needs unexpected surgery, they are at risk of death from uncontrollable bleeding.
Need a Texas Xarelto Lawyer?
Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged.
"Collen’s amazing success in the courtroom and well known dedication to his clients has earned him the recognition of his peers as one of The Top Trial Lawyers in Texas.”
The Clark Firm has assembled a team of trial lawyers with more than 100 years experience, participation in over 600 jury trials and $260 million in verdicts and/or settlements. Please use the form below to contact our Texas Xarelto lawyers for a free lawsuit review.
https://www.theclarkfirmtexas.com/nearly-1500-people-have-joined-xarelto-litigation
-
Xarelto, Pradaxa Bleeding Risks The Same As Warfarin: Study
Aug 7, 2015 | AboutLawsuits.com
By Irvin Jackson
New research suggests that the blood thinners Xarelto and Pradaxa are no safer than warfarin when it comes to bleeding and arterial thromboembolic events like heart attacks and strokes. The findings raise further concerns about the new-generation anticoagulants, as they lack an approved reversal agent, which makes it harder for doctors to stop bleeding events that do occur.
In a study published in the American Heart Association’s medical journal Circulation on July 21, researchers from the France’s National Health Insurance Strategy and Research Department report that they found no significant difference in the rate of bleeding events, strokes or heart attacks among patients using either Xarelto, Pradaxa or some form of vitamin K agonist (VKA), which is an older class of blood thinners that includes Coumadin (warfarin).
Researchers were specifically looking at the safety and efficacy of the drugs during the early phases of treatment, when patients first begin using them as a preventative measure to avoid strokes caused by nonvalvular atrial fibrillation. The nationwide cohort study used data on 19,713 VKA users, 8,443 Pradaxa users, and 4,651 Xarelto patients.
Pradaxa and Xarelto are two of a group of new blood thinners, often referred to as novel oral anticoagulants (NOACs), which are promoted as superior to warfarin since they require less testing, and are advertised as safer. However, they have come under fire for not being released with a reversal agent, meaning that when bleeding events do occur, doctors often find them hard to stop.
The blood thinning effect of warfarin and other vitamin K agonists can be quickly stopped through the use of an antidote. However, doctors have reported more serious bleeding events on Xarelto and Pradaxa, due to the lack of an effective reversal agent.
Researchers found no statistically significant difference in the risk of bleeding events or arterial thromboembolism events between any of the three groups for the first 90 days of use. They said that while that appears to back up some claims made by previous studies suggesting that the newer drugs were safe, the findings also raised some concerns specifically due to the lack of a reversal agent, or antidote, and the decision not to monitor patients given Pradaxa and Xarelto.
“NOAC cannot be considered to be safer than VKA during the early phase of treatment,” the researchers concluded. “On the contrary, the clinical implications of our results are that physicians must be just as cautious when initiating NOAC as when initiating VKA, particularly in view of the absence of an antidote and objective monitoring of the extent of anticoagulation.”
New Blood Thinner Bleeding Risks
Pradaxa was introduced by Boehringer Ingelheim in late 2010 as the first member of a new class of anticoagulants. Xarelto was introduced by Bayer and Janssen Pharmaceuticals in 2011, as the second member of this class.
While all blood thinners carry a risk of bleeding injury, Pradaxa and Xarelto have been linked to a surprising number of problems as more and more patients are switched from warfarin to the new anticoagulants.
In addition to the lack of a reversal agent, several recent studies have also raised questions about the marketing claims made by the makers of these new anticoagulants, suggesting that blood monitoring may actually help doctors identify patients at the greatest risk of bleeding.
In July 2014, an investigative report published by The BMJ suggested that the makers of Pradaxa failed to provide the FDA with important clinical trial data that suggested users may benefit from regular blood monitoring to make sure the drug did not build up in their bloodstream, increasing the risk of bleeds.
In another study published by the Journal of Cardiology in October 2014, researchers indicated that Xarelto monitoring may have helped doctors understand the effects of the drug on a particular patient and their associated bleeding risk.
Boehringer Ingelheim faced more than 4,000 Pradaxa lawsuits that allege inadequate warnings were provided about the lack of an available reversal agent for their medication. Following several years of litigation, the drug maker agreed to pay $650 million in Pradaxa settlements last year, with an average of about $150,000 awarded to former users who experienced injuries associated with uncontrollable bleeds.
Xarelto (rivaroxaban) was the second member of this new class of anticoagulants to be approved by the FDA, hitting the market about a year after Pradaxa. However, as Boehringer Ingelheim faced mounting lawsuits and publicity over severe bleeding events associated with Pradaxa, Xarelto has overtaken the top spot among the new medications, with sales exceeding those of Pradaxa in 2013.
A growing number of Xarelto bleeding lawsuits are now being pursued on behalf of former users, raising similar allegations that inadequate warnings were provided about the lack of an approved reversal agent and claiming that the drug makers should have never introduced the medication without an antidote to allow doctors to reverse bleeding events.
http://www.aboutlawsuits.com/xarelto-pradaxa-bleeding-study-85765/
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Add recipients
Suggested